{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:33:10Z","timestamp":1771342390002,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00774-020-01169-z","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T12:04:43Z","timestamp":1605528283000},"page":"430-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Etelcalcetide decreases the PTH\u2013calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism"],"prefix":"10.1007","volume":"39","author":[{"given":"Noriyuki","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-2631","authenticated-orcid":false,"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoe","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikue","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Miyaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhito","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuto","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutsune","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S2213-8587(17)30310-8","volume":"6","author":"A Covic","year":"2018","unstructured":"Covic A, Vervloet M, Massy ZA, Torres PU, Goldsmith D, Brandenburg V, Mazzaferro S, Evenepoel P, Bover J, Apetrii M, Cozzolino M (2018) Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol 6:319\u2013331","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1169_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478\u20131483","journal-title":"N Engl J Med"},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1681\/ASN.V12102131","volume":"12","author":"SK Ganesh","year":"2001","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131\u20132138","journal-title":"J Am Soc Nephrol"},{"key":"1169_CR5","unstructured":"Imanishi Y, Nishizawa Y, Inaba M (2013) Chapter 5 Pathogenesis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. In: Suzuki H, (ed.) Hemodialysis. InTech: Rijeka, Croatia; 81\u2013100"},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00774-006-0687-y","volume":"24","author":"T Kawata","year":"2006","unstructured":"Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, Komo T, Tahara H, Wada M, Nagano N, Ishimura E, Miki T, Ishikawa T, Inaba M, Nishizawa Y (2006) Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab 24:300\u2013306","journal-title":"J Bone Miner Metab"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO), CKD-MBD Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO), CKD-MBD Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"1169_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T et al (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17:247\u2013288","journal-title":"Ther Apher Dial"},{"key":"1169_CR9","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","volume":"95","author":"EF Nemeth","year":"1998","unstructured":"Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 95:4040\u20134045","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1677\/jme.0.0290015","volume":"29","author":"EF Nemeth","year":"2002","unstructured":"Nemeth EF (2002) The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol 29:15\u201321","journal-title":"J Mol Endocrinol"},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D (2004) Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308:627\u2013635","journal-title":"J Pharmacol Exp Ther"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/mol.115.098392","volume":"88","author":"ST Alexander","year":"2015","unstructured":"Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, Subramanian R, Tomlinson JE (2015) Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol 88:853\u2013865","journal-title":"Mol Pharmacol"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F (2013) Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"1169_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1172\/JCI10523","volume":"107","author":"Y Imanishi","year":"2001","unstructured":"Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093\u20131102","journal-title":"J Clin Invest"},{"key":"1169_CR15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1359\/jbmr.2002.17.9.1656","volume":"17","author":"Y Imanishi","year":"2002","unstructured":"Imanishi Y, Hall C, Sablosky M, Brown EM, Arnold A (2002) A new method for in vivo analysis of parathyroid hormone-calcium set point in mice. J Bone Miner Res 17:1656\u20131661","journal-title":"J Bone Miner Res"},{"key":"1169_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1210\/jcem-56-3-572","volume":"56","author":"EM Brown","year":"1983","unstructured":"Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572\u2013581","journal-title":"J Clin Endocrinol Metab"},{"key":"1169_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1517\/17460440903022743","volume":"4","author":"Y Imanishi","year":"2009","unstructured":"Imanishi Y, Inaba M, Kawata T, Nishizawa Y (2009) Animal models of hyperfunctioning parathyroid diseases for drug development. Expert Opin Drug Discov 4:727\u2013740","journal-title":"Expert Opin Drug Discov"},{"key":"1169_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1530\/eje.1.02007","volume":"153","author":"T Kawata","year":"2005","unstructured":"Kawata T, Imanishi Y, Kobayashi K, Kenko T, Wada M, Ishimura E, Miki T, Nagano N, Inaba M, Arnold A, Nishizawa Y (2005) Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 153:587\u2013594","journal-title":"Eur J Endocrinol"},{"key":"1169_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00223-011-9490-4","volume":"89","author":"Y Imanishi","year":"2011","unstructured":"Imanishi Y, Kawata T, Kenko T, Wada M, Nagano N, Miki T, Arnold A, Inaba M (2011) Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism. Calcif Tissue Int 89:29\u201335","journal-title":"Calcif Tissue Int"},{"key":"1169_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejphar.2018.10.021","volume":"842","author":"K Harada","year":"2019","unstructured":"Harada K, Fujioka A, Konno M, Inoue A, Yamada H, Hirota Y (2019) Pharmacology of Parsabiv((R)) (etelcalcetide, ONO-5163\/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients. Eur J Pharmacol 842:139\u2013145","journal-title":"Eur J Pharmacol"},{"key":"1169_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/0002-9343(79)90446-7","volume":"66","author":"EM Brown","year":"1979","unstructured":"Brown EM, Gardner DG, Brennan MF, Marx SJ, Spiegel AM, Attie MF, Downs RW Jr, Doppman JL, Aurbach CD (1979) Calcium-regulated parathyroid hormone release in primary hyperparathyroidism: studies in vitro with dispersed parathyroid cells. Am J Med 66:923\u2013931","journal-title":"Am J Med"},{"key":"1169_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jcem-54-1-172","volume":"54","author":"EM Brown","year":"1982","unstructured":"Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick SP (1982) Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54:172\u2013179","journal-title":"J Clin Endocrinol Metab"},{"key":"1169_CR23","doi-asserted-by":"publisher","first-page":"51739","DOI":"10.1074\/jbc.M406164200","volume":"279","author":"HC Mun","year":"2004","unstructured":"Mun HC, Franks AH, Culverston EL, Krapcho K, Nemeth EF, Conigrave AD (2004) The Venus Fly Trap domain of the extracellular Ca2+ -sensing receptor is required for l-amino acid sensing. J Biol Chem 279:51739\u201351744","journal-title":"J Biol Chem"},{"key":"1169_CR24","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.1074\/jbc.M110.149724","volume":"286","author":"GK Broadhead","year":"2011","unstructured":"Broadhead GK, Mun HC, Avlani VA, Jourdon O, Church WB, Christopoulos A, Delbridge L, Conigrave AD (2011) Allosteric modulation of the calcium-sensing receptor by gamma-glutamyl peptides: inhibition of PTH secretion, suppression of intracellular cAMP levels, and a common mechanism of action with l-amino acids. J Biol Chem 286:8786\u20138797","journal-title":"J Biol Chem"},{"key":"1169_CR25","doi-asserted-by":"publisher","first-page":"18990","DOI":"10.1074\/jbc.M400724200","volume":"279","author":"C Petrel","year":"2004","unstructured":"Petrel C, Kessler A, Dauban P, Dodd RH, Rognan D, Ruat M (2004) Positive and negative allosteric modulators of the Ca2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J Biol Chem 279:18990\u201318997","journal-title":"J Biol Chem"},{"key":"1169_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00223-017-0319-7","volume":"101","author":"L Yu","year":"2017","unstructured":"Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D, Stolina M, Dean C Jr, Goodman WG, Richards WG, Li X (2017) Etelcalcetide, a novel calcimimetic, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism. Calcif Tissue Int 101:641\u2013653","journal-title":"Calcif Tissue Int"},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","volume":"67","author":"M Colloton","year":"2005","unstructured":"Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467\u2013476","journal-title":"Kidney Int"},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0960-0760(99)00112-0","volume":"70","author":"Y Imanishi","year":"1999","unstructured":"Imanishi Y, Inaba M, Seki H, Koyama H, Nishizawa Y, Morii H, Otani S (1999) Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells. J Steroid Biochem Mol Biol 70:243\u2013248","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01169-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01169-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01169-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T04:36:49Z","timestamp":1619671009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01169-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01169-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YI, KM, ME, and MI received lecture fees from ONO Pharmaceutical Co., Ltd., Osaka, Japan. AI and KH are employees of ONO Pharmaceutical Co., Ltd., Osaka, Japan. NH, TH, IK, TT, DM, YN, and TM declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}